Annual Development Plan. 7.1 The Partners shall prepare an Annual Development Plan for each of the Services at least four weeks before the start of the Financial Year. The Annual Development Plan shall:
Annual Development Plan. Not later than sixty (60) days after December 31 of each Calendar Year, Licensee shall submit to Merck an updated Development Plan for the pending Calendar Year. Such update shall take into account completion, commencement, changes in or cessation of Development activities not contemplated by the then-current Development Plan in sufficient detail to reflect the Commercially Reasonable Efforts of Licensee or a Related Party for the Development of Licensed Product in the Field. Merck shall have the right to comment on such annual plan. In the event Merck reasonably disagrees with the plan, Licensee shall in good faith consider Merck’s comments for revising the plan; provided, however, that Licensee shall not be obligated to incorporate such Merck comments and Licensee retains final decision making authority with respect to all such plans.
Annual Development Plan. The Development Phase shall be conducted under an annual development plan which shall describe the work to be pursued by MMD and TKT under the supervision of the Development Committee with respect to the development of * . The first Development Plan will be prepared by MMD for submission to the Development Committee ************************************************************* ***************************************************************. Thereafter, the annual development plan will be prepared by MMD for submission to the Development Committee no later than sixty (60) days prior to the beginning of each calendar year.
Annual Development Plan. The Development Program shall be conducted under an annual research and development plan (the "Annual Development Plan") which shall reasonably describe the work to be pursued by the Joint Steering Committee and to be conducted by Metasyn and MKG with respect to the development of the Licensed Compound, any Second Generation Compounds, the Replacement Compounds and any Outside Compounds and the corresponding Licensed Products. The Annual Development Plan shall contain a budget including estimates of the aggregate Development Costs of both Parties to be incurred during the applicable year. The Annual Development Plan will incorporate the Base Case Scenario Model (as the model may have been amended by the Joint Steering Committee in accordance with Section 6.1 hereof and as it may be applicable). The first Annual Development Plan describing the expenses and activities anticipated for the period between the Effective Date and December *Confidential information omitted and filed with the Commission. 11
Annual Development Plan. Not later than sixty (60) days after December 31 of each Calendar Year, Licensee shall submit to Lilly an updated Development Plan for the pending Calendar Year. Such update shall take into account the anticipated Development activities, for the applicable development period, of Licensee or a Related Party for the Development of Licensed Product in the Field. Lilly shall have the right to comment on such annual plan, provided, however, that Licensee shall not be obligated to incorporate such Lilly comments and Licensee retains final decision making authority with respect to all such plans.
Annual Development Plan. No later than [***] days after the end of each Calendar Year, Tigercat shall submit to Merck an updated Development Plan for the then current Calendar Year. Such update shall take into account completion, commencement, changes in or cessation of Development activities in sufficient detail to reflect the continued diligence of Tigercat. Merck shall have the right to comment on such updated Development Plan, but Tigercat shall have sole decision-making rights with respect to such Development Plan.
Annual Development Plan. Not later than [**] days after December 31 of each Calendar Year, Licensee shall submit to Merck an updated Development Plan for the pending Calendar Year. Such update shall take into account completion, commencement, changes in or cessation of Development activities not contemplated by the then-current Development Plan in sufficient detail to reflect the continued diligence of Licensee and shall reflect effort and resources consistent with other priority projects of Licensee. Merck shall have the right to comment on such annual plan. In the event Merck reasonably disagrees with the plan, Licensee shall consider in good faith Merck’s comments for revising the plan. At Merck’s written request, the President of Merck’s research division, or his designee, and the President of Licensee’s research division or equivalent position, or her designee, shall meet to discuss such comments. Any revision of the annual plan shall be submitted to Merck promptly after its completion.
Annual Development Plan. Not later than thirty (30) days after December 31 of each Calendar Year, Licensee shall submit to Merck an updated Development Plan for the pending Calendar Year. Such update shall take into account completion, commencement, changes in or cessation of Development activities not contemplated by the then-current Development Plan sufficient to reflect that Diligent Efforts are being undertaken by Licensee with respect to Licensed Compound. The updated Development Plan shall also describe Licensee’s progress with respect to its Development efforts under this Agreement and shall include the following information for Licensed Product: a description of the Development work to be conducted during the year in reasonable detail, including clinical studies, formulation work, manufacturing work, other testing work and regulatory activity; timelines for such work; and key decision gates and milestones for such work. Merck shall have the right to comment on such annual plan. In the event Merck reasonably disagrees with the plan, Licensee shall consider Merck’s comments for revising the plan. At Merck’s written request, the President of Merck’s research division, or his designee, and the President of Licensee’s research division or equivalent position, or his designee, shall meet to discuss such comments and, if Licensee so chooses, the changes can be incorporated into a revised annual Development Plan. Any revision of the annual plan shall be submitted to Merck promptly after its completion.
Annual Development Plan. Pharmion shall annually prepare a development plan for the forthcoming calendar year describing the steps which Pharmion desires to take for the development of Additional Indications or New Presentations for the Product during the forthcoming calendar year (each a "Development Plan"). Each such Development Plan shall be treated by both Parties as a good faith statement of Pharmion's intentions for the forthcoming year, but such Development Plan shall not be deemed to be a contractual commitment by Pharmion to undertake all of the efforts described in such Plan or to achieve the goals contained in such Plan. Each such Development Plan shall be presented for approval to the Development and Marketing Committee as contemplated by Section 5.5 below.
Annual Development Plan. Not later than thirty (30) days after December 31 of each Calendar Year, Licensee shall submit to Schering an updated Development Plan for the pending Calendar Year. Such update shall take into account completion, commencement, changes in or cessation of Development activities not contemplated by the then-current Development Plan in sufficient detail to reflect the continued diligence of Licensee and shall reflect effort and resources consistent with other priority projects of Licensee. Schering shall have the right to comment on such annual plan. In the event Schering reasonably disagrees with the plan, Licensee shall consider Schering’s comments for revising the plan. At Schering’s written request, the President of Schering’s research division, or his designee, and the President of Licensee’s research division or equivalent position, or his designee, shall meet to discuss such comments. Any revision of the annual plan shall be submitted to Schering promptly after its completion.
